Рет қаралды 5,399
The FDA has given approval to Axsome Therapeutics’ depression drug Auvelity, making it the first and only rapid-acting oral medication approved for the treatment of major depressive disorder (MDD). It is also the first and only oral NMDA receptor antagonist approved for the condition. Hear more about the approval, including its novel mechanism of action and the clinical trial data that supported its approval.
Register for our free featured webinar, "Transparency and Self-Service: Keys to Data Management Solutions’ Success" here:
xtalks.com/web...
Read more on this story "Axsome’s Auvelity Wins FDA Approval as First Rapid-Acting Oral Treatment for Depression" here:
xtalks.com/axs...
Receive weekly news and webinar updates right in your inbox: xtalks.com/reg...
Listen live and interact with featured speakers on our upcoming Life Science webinars: bit.ly/2YRzAV0